2019
Effects of Mobile Text Messaging on Glycemic Control in Patients With Coronary Heart Disease and Diabetes Mellitus
Huo X, Krumholz HM, Bai X, Spatz ES, Ding Q, Horak P, Zhao W, Gong Q, Zhang H, Yan X, Sun Y, Liu J, Wu X, Guan W, Wang X, Li J, Li X, Spertus JA, Masoudi FA, Zheng X. Effects of Mobile Text Messaging on Glycemic Control in Patients With Coronary Heart Disease and Diabetes Mellitus. Circulation Cardiovascular Quality And Outcomes 2019, 12: e005805. PMID: 31474119, DOI: 10.1161/circoutcomes.119.005805.Peer-Reviewed Original ResearchMeSH KeywordsAgedAsian PeopleBiomarkersBlood GlucoseChinaCoronary DiseaseCulturally Competent CareDiabetes MellitusExerciseFemaleGlycated HemoglobinHealth CommunicationHealthy LifestyleHumansHypoglycemic AgentsMaleMedication AdherenceMiddle AgedMotivationPatient Education as TopicRisk Reduction BehaviorSelf CareSingle-Blind MethodTelemedicineText MessagingTime FactorsTreatment OutcomeConceptsCoronary heart diseaseHeart diseaseGlycemic controlIntervention groupUsual careDiabetes mellitusBlood glucosePhysical activityControl groupText message-based interventionBlood pressure controlProportion of patientsRisk factor managementGood glycemic controlSystolic blood pressureBody mass indexText messaging programsText message interventionMobile health interventionsSecondary outcomesBlood pressurePrimary outcomeLDL cholesterolMass indexMedication adherence
2017
Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and the CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomised controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes
Huo X, Spatz ES, Ding Q, Horak P, Zheng X, Masters C, Zhang H, Irwin ML, Yan X, Guan W, Li J, Li X, Spertus JA, Masoudi FA, Krumholz HM, Jiang L. Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and the CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomised controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes. BMJ Open 2017, 7: e018302. PMID: 29273661, PMCID: PMC5778311, DOI: 10.1136/bmjopen-2017-018302.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood PressureChinaCoronary DiseaseDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2ExerciseFemaleGlycated HemoglobinHumansLife StyleMaleMedication AdherenceMiddle AgedMotivationResearch DesignRisk FactorsSecondary PreventionSelf CareSingle-Blind MethodTelemedicineText MessagingYoung AdultConceptsSystolic blood pressureBody mass indexTrials of textProportion of patientsMedication adherencePhysical activitySecondary outcomesPrimary outcomeSmoking cessationCardiovascular healthMellitus StudySecondary coronary heart disease preventionCoronary heart disease preventionLow-density lipoprotein cholesterolUsual scientific forumsBlood pressure controlRisk factor managementHeart disease preventionCoronary heart diseaseMobile health interventionsInstitutional review boardUniversity Institutional Review BoardBehavioral skills modelText messagingBehavioral change techniquesHemoglobin A1c as a Surrogate for Clinical Outcomes in Diabetes Studies—Reply
Lipska KJ, Krumholz HM. Hemoglobin A1c as a Surrogate for Clinical Outcomes in Diabetes Studies—Reply. JAMA 2017, 318: 200-201. PMID: 28697251, DOI: 10.1001/jama.2017.7225.Peer-Reviewed Original ResearchIs Hemoglobin A1c the Right Outcome for Studies of Diabetes?
Lipska KJ, Krumholz HM. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes? JAMA 2017, 317: 1017-1018. PMID: 28125758, PMCID: PMC5350060, DOI: 10.1001/jama.2017.0029.Commentaries, Editorials and Letters
2016
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care 2016, 40: 468-475. PMID: 27659408, PMCID: PMC5360291, DOI: 10.2337/dc16-0985.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBlood GlucoseComorbidityDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug UtilizationFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinLogistic ModelsMaleMetforminMiddle AgedRetrospective StudiesSulfonylurea CompoundsThiazolidinedionesYoung AdultConceptsGlycemic controlSevere hypoglycemiaOlder patientsDipeptidyl peptidase-4 inhibitorsGlucose-lowering drugsGlucose-lowering medicationsProportion of patientsOverall glycemic controlPeptidase-4 inhibitorsMedicare Advantage patientsSex-standardized ratesType 2 diabetesOverall rateClass of agentsMore comorbiditiesChronic comorbiditiesYounger patientsAdvantage patientsDrug utilizationClaims dataPatientsHypoglycemiaHemoglobin AT2DMComorbiditiesPolypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes
Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA 2016, 315: 1034-1045. PMID: 26954412, PMCID: PMC4823136, DOI: 10.1001/jama.2016.0299.BooksConceptsRandomized clinical trialsIntensive glycemic controlGlycemic controlClinical trialsOlder adultsMicrovascular outcomesTreatment burdenPatient preferencesMost RCTsLarge randomized clinical trialsType 2 diabetes mellitusMajor macrovascular eventsStandard glycemic controlOptimal glycemic controlLower treatment burdenSurrogate end pointsHigh-quality evidenceType 2 diabetesLikelihood of benefitMajority of adultsGlycemic treatmentMacrovascular eventsDiabetes mellitusPatient factorsAging Patient
2013
HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes
Lipska KJ, Warton EM, Huang ES, Moffet HH, Inzucchi SE, Krumholz HM, Karter AJ. HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes. Diabetes Care 2013, 36: 3535-3542. PMID: 23900589, PMCID: PMC3816866, DOI: 10.2337/dc13-0610.Peer-Reviewed Original ResearchConceptsSevere hypoglycemiaType 2 diabetesRelative riskGlycemic controlSelf-reported severe hypoglycemiaType 2 diabetic patientsGlucose-lowering therapyPoor glycemic controlRate of hypoglycemiaPotential effect modifiersIntegrated healthcare systemYears of ageEligible survey respondentsPoisson regression modelsDiabetes durationDiabetes medicationsDiabetic patientsClinical variablesDiabetes StudyNormal glycemiaMain exposureEffect modifiersHypoglycemiaType 2Patients
2012
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR, Smith SC, Spertus JA, Williams SV. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal Of The American College Of Cardiology 2012, 60: e44-e164. PMID: 23182125, DOI: 10.1016/j.jacc.2012.07.013.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdrenergic beta-AntagonistsAlcohol DrinkingAngina PectorisBody WeightCholesterol, LDLClopidogrelComorbidityCost of IllnessDepressionDiabetes ComplicationsDisease ManagementElectrocardiographyExerciseExercise TestGlycated HemoglobinHealth BehaviorHumansHypertensionLife StyleMyocardial InfarctionMyocardial IschemiaMyocardial RevascularizationPhysical ExaminationPlatelet Aggregation InhibitorsPractice Guidelines as TopicQuality of LifeRisk AssessmentRisk FactorsRisk Reduction BehaviorSmoking CessationTiclopidineConceptsAmerican CollegeAmerican Heart Association Task ForcePreventive Cardiovascular Nurses AssociationCardiology Foundation/American Heart Association Task ForceManagement of patientsThoracic surgeryPractice guidelinesCardiovascular AngiographyThoracic surgeonsSTS guidelinesA ReportNurses AssociationAmerican AssociationTask ForceAssociationGuidelinesPatientsSurgeryAngiographyPhysiciansDiagnosisSurgeonsRole of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis
Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. JAMA Internal Medicine 2012, 172: 761-769. PMID: 22636820, PMCID: PMC3688081, DOI: 10.1001/archinternmed.2011.2230.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood GlucoseDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionFemaleGlycated HemoglobinHumansHypoglycemic AgentsKidney Failure, ChronicKidney Function TestsMaleMiddle AgedMonitoring, PhysiologicPrognosisRandomized Controlled Trials as TopicRenal DialysisRisk AssessmentSeverity of Illness IndexConceptsIntensive glucose controlRenal end pointsSerum creatinine levelsConventional glucose controlGlucose controlType 2 diabetesRenal diseaseCreatinine levelsEnd pointGlycemic controlSystematic reviewType 2 diabetes mellitusAggressive glycemic controlClinical renal outcomesKidney-related outcomesIntensive glycemic controlRenal outcomesCumulative incidenceDiabetes mellitusRandomized trialsConventional therapyLanguage restrictionsMacroalbuminuriaMicroalbuminuriaType 2
2011
Use of GLP-1 analogues needs great caution
Yudkin JS, Lehman R, Krumholz HM. Use of GLP-1 analogues needs great caution. The BMJ 2011, 342: d1478. PMID: 21385813, DOI: 10.1136/bmj.d1478.Peer-Reviewed Original Research
2010
No to QOF target of less than 7%, again
Lehman R, Krumholz HM. No to QOF target of less than 7%, again. The BMJ 2010, 340: c985. PMID: 20179124, DOI: 10.1136/bmj.c985.Peer-Reviewed Original ResearchImportance of Measuring Glycosylated Hemoglobin in Patients With Myocardial Infarction and Known Diabetes Mellitus
Stolker JM, Sun D, Conaway DG, Jones PG, Masoudi FA, Peterson PN, Krumholz HM, Kosiborod M, Spertus JA. Importance of Measuring Glycosylated Hemoglobin in Patients With Myocardial Infarction and Known Diabetes Mellitus. The American Journal Of Cardiology 2010, 105: 1090-1094. PMID: 20381658, PMCID: PMC2856846, DOI: 10.1016/j.amjcard.2009.12.010.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionDiabetes mellitusMyocardial infarctionChronic glycemic controlPoor controlMyocardial infarction patientsProspective registryGlycemic controlClinical outcomesGlycosylated hemoglobinHemoglobin assessmentInfarction patientsAMI careDM controlDM treatmentHospital levelPatientsDisease managementAdditional quality indicatorsMarked variabilityMellitusInfarctionCurrent performance measuresDM evaluationAssessment
2009
Tight control of blood glucose in long standing type 2 diabetes
Lehman R, Krumholz HM. Tight control of blood glucose in long standing type 2 diabetes. The BMJ 2009, 338: b800. PMID: 19264821, DOI: 10.1136/bmj.b800.Peer-Reviewed Original ResearchMeSH KeywordsBlood GlucoseDiabetes Mellitus, Type 2Diabetic AngiopathiesFemaleGlycated HemoglobinHumansPregnancy